Liver-specific gadoxetic acid-enhanced magnetic resonance for focal lesion evaluation.
Gadolinium-enhanced magnetic resonance for the evaluation of hepatic lesions is increasingly being used in clinical practice, especially in patients with suspicious focal lesions, whether benign or malignant. In regard to hepatocellular carcinoma, the diagnostic performance of magnetic resonance through the «conventional» protocols and multi-detector computerized tomography consisting of multiphase evaluation with intravenous contrast, largely depends on the size of the lesion. They are more reliable in lesions>2cm. However, in lesions measuring 1-2cm, establishing the definitive diagnosis is a real challenge, with sensitivity values of 45-65%, but generally with excellent specificity (>95%). Furthermore, if the lesion has a diameter<1cm, diagnosis is usually unreliable. In these last 2 settings, the complementary use of liver-specific contrast agents can be advantageous. The aim of our article was to review the current evidence on the usefulness of this new non-invasive diagnostic method in hepatic lesions.
Grupo C.T. Scanner, México, D.F., México.
P E
PE
Cossio-Torrico
Unidad de Resonancia Magnética, Grupo C.T. Scanner Lomas Altas, México, D.F., México.
C R
CR
Ramírez-Carmona
Grupo C.T. Scanner Lomas Altas, México, D.F., México.
M
M
Stoopen-Rometti
Unidad de Resonancia Magnética, Grupo C.T. Scanner Lomas Altas, México, D.F., México.
A
A
Perochena-González
Unidad de Resonancia Magnética, Grupo C.T. Scanner de México, México, D.F., México.
L A
LA
Sosa-Lozano
Grupo C.T. Scanner Lomas Altas, México, D.F., México. Electronic address: ekimura@ctscanner.mx.
E
E
Kimura-Hayama
D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging*; D003287:Contrast Media; D019786:Gadolinium DTPA; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D012680:Sensitivity and Specificity
D003287:Contrast Media; C073590:gadolinium ethoxybenzyl DTPA; D019786:Gadolinium DTPA
Carcinoma hepatocelular; Contrastes hepatoespecíficos; Fase hepatobiliar; Gadoxetic acid; Hepatobiliary phase; Hepatocellular carcinoma; Liver-specific contrast agents; Ácido gadoxético